DERM Journey Medical Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: DERM

Price (delayed)

$6.23

Market cap

$171.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.37

Enterprise value

$169.79M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 20
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 29

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated ...

Highlights
DERM's EPS is up by 21% since the previous quarter and by 5% year-on-year
The company's gross profit rose by 16% YoY and by 3.4% QoQ
The equity is up by 43% year-on-year but it has declined by 3.2% since the previous quarter
The company's quick ratio rose by 42% YoY but it fell by 4.2% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: https://journeymedicalcorp.com
Peers: BHC PRGO TEVA AMRX

Key stats

What are the main financial stats of DERM

DERM stock price

How has the Journey Medical stock price performed over time
Intraday
2.81%
1 week
0.48%
1 month
21.68%
1 year
-16.38%
YTD
-19.2%
QTD
32.84%

Financial performance

How have Journey Medical's revenue and profit performed over time
Revenue
$64.68M
Gross profit
$42.33M
Operating income
-$6.34M
Net income
-$9.59M
Gross margin
65.4%
Net margin
-14.8%
DERM's operating margin is up by 26% QoQ and by 20% YoY
Journey Medical's operating income has increased by 22% QoQ and by 8% YoY
The net margin is up by 20% QoQ
Journey Medical's net income has increased by 16% QoQ but it has decreased by 15% YoY

Price vs fundamentals

How does DERM's price correlate with its fundamentals

Growth

What is Journey Medical's growth rate over time

Valuation

What is Journey Medical stock price valuation
P/E
N/A
P/B
5.52
P/S
2.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.63
DERM's EPS is up by 21% since the previous quarter and by 5% year-on-year
DERM's price to book (P/B) is 98% lower than its 5-year quarterly average of 324.9 and 17% lower than its last 4 quarters average of 6.5
The equity is up by 43% year-on-year but it has declined by 3.2% since the previous quarter
DERM's price to sales (P/S) is 83% higher than its 5-year quarterly average of 1.4 but 5% lower than its last 4 quarters average of 2.7
The revenue is up by 15% year-on-year and by 4.6% since the previous quarter

Efficiency

How efficient is Journey Medical business performance
DERM's ROE is up by 32% YoY and by 23% QoQ
The ROIC rose by 30% QoQ and by 25% YoY
DERM's return on sales is up by 27% since the previous quarter and by 2.2% year-on-year
Journey Medical's return on assets has increased by 17% QoQ and by 3.5% YoY

Dividends

What is DERM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DERM.

Financial health

How did Journey Medical financials performed over time
The company's total assets is 51% higher than its total liabilities
The company's quick ratio rose by 42% YoY but it fell by 4.2% QoQ
Journey Medical's current ratio has increased by 28% YoY but it has decreased by 3.9% from the previous quarter
The debt is 17% lower than the equity
The equity is up by 43% year-on-year but it has declined by 3.2% since the previous quarter
DERM's debt to equity is down by 29% year-on-year but it is up by 3.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.